Simultaneous inhibition of PARP/AKT to intercept nascent BRCA1/2<sup>mut</sup> breast tumors.

The median tumor-specific survival of mice treated with PARPi+AKTi (120 days) or PARPi alone (117 days) was longer than controls but highly variable, and this difference did not reach statistical significance ( p = 0.11 and p = 0.33, respectively; Fig. 2B ); the effect size, an improvement of about 40 days, was much smaller than in the interception study.

also in 111,027 other papers

The PARPi+AKTi arm also had 44% lower risk of cancer progression compared to PARPi but this finding did not achieve significance (RR 0.56, p = 0.37).

also in 1,397 other papers